Coronary microvascular dysfunction (CMD) and heart failure with preserved ejection fraction (HFpEF) Circulatory System
Conditions
Interventions
This study comprises an invasive and non-invasive observational arm as well as a phenotype-blinded therapeutic arm.
In the observational arm, participants undergo invasive characterisation in the ca
the exercise will be supervised by a member of the research team.
In the phenotype-blinded therapeutic arm, participants and researchers are blinded to the characterisation performed in the aforemen
Sponsors
King's College London
Guy's and St Thomas' NHS Foundation Trust
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Indication for coronary angiography AND a 2. Clinical diagnosis of HFpEF
Exclusion criteria
Exclusion criteria: 1. Severe valvular disease 2. Significant epicardial coronary stenoses 3. Congenital heart disease 4. Suspected infiltrative heart disease (echo or CMR) 5. Inability to perform ambulatory, hand grip or cycle ergometric exercises 6. Pregnancy 7. Concurrent enrolment in a CTIMP trial
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Ratio between the normalised delta of pulmonary capillary wedge pressure and 'exercise flow reserve' (i.e. the ratio between filling pressures and changes in coronary blood flow on exercise), measured once during the study’s invasive assessment | — |
Secondary
| Measure | Time frame |
|---|---|
| 6-minute walk distance (6MWD) on anti-ischaemic treatment versus baseline, measured in metres at baseline, post 4 weeks of ranolazine administration and post 4 weeks off of ranolazine | — |
Countries
England, United Kingdom
Contacts
Public ContactBecker Al-Khayatt
Outcome results
None listed